FibroBiologics, Inc. (NASDAQ: FBLG) has completed the first cGMP‑manufactured batch of its investigational fibroblast‑based therapy, CYWC628, clearing the company to begin enrollment in a Phase 1/2 clinical trial for diabetic foot ulcers (DFUs). The product met all FDA cGMP requirements and passed comprehensive safety and quality testing, enabling the company to move from manufacturing to active clinical testing.
CYWC628 delivers a spheroid‑based fibroblast therapy that preclinical studies have shown can accelerate DFU healing. The trial, scheduled to begin in Australia in Q1 2026, will enroll patients with chronic DFUs and collect safety and early efficacy data that could support future regulatory submissions and partnership opportunities.
The milestone comes as FibroBiologics continues to navigate financial challenges. The company reported a net loss of approximately $5.0 million for Q1 2026, up from a $1.8 million loss in Q1 2025, and held about $1.5 million in cash and cash equivalents as of March 31 2026. A $3 million direct offering in April 2026 helped shore up liquidity but left the company with limited runway.
Despite the financial headwinds, the release of CYWC628 is a key step toward generating data that could unlock non‑dilutive capital and improve the company’s liquidity position. Analysts have expressed mixed views: H.C. Wainwright maintained a Buy rating and raised its price target to $8.00, while Maxim Group downgraded the stock to Hold, citing concerns about profitability and growth prospects.
The company’s broader pipeline includes candidates for psoriasis (CYPS317), multiple sclerosis (CYMS101), burn wounds, and degenerative disc disease, all of which are in preclinical or IND‑enabling stages. The successful manufacturing of CYWC628 also reinforces FibroBiologics’ strong patent portfolio of over 270 issued and pending patents, supporting its fibroblast‑based technology platform.
Investor sentiment has been cautious, reflecting concerns about the company’s financial health and the recent analyst downgrade, which tempered enthusiasm for the operational milestone.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.